Methionine aminopeptidase 是一种在蛋白质生物合成中起关键作用的酶。MetAP 负责从新生多肽链上切除 N 端的蛋氨酸残基,这对于许多蛋白质的正确折叠、成熟和功能至关重要。MetAP1 和 MetAP2 具有不同的亚细胞定位和底物特异性。MetAP1 主要参与胞质蛋白的加工。MetAP2 在癌症研究中特别受关注,因为它参与血管生成,并且已成为抗癌药物开发的靶点。抑制 MetAP2 可以通过干扰某些参与血管生成的蛋白质的加工来破坏癌细胞的生长和增殖[1][2]。
Methionine aminopeptidase (MetAP) is an enzyme that plays a crucial role in protein biosynthesis. MetAP is responsible for the removal of the N-terminal methionine residue from nascent polypeptide chains, which is essential for the proper folding, maturation and function of many proteins. MetAP1 and MetAP2 have different subcellular localizations and substrate specificities. MetAP1 is mainly involved in the processing of cytosolic proteins. MetAP2 is of particular interest in cancer research as it is involved in angiogenesis and has been targeted for anti-cancer drug development. Inhibition of MetAP2 can disrupt the growth and proliferation of cancer cells by interfering with the processing of certain proteins involved in angiogenesis[1][2].
Fumagilin-105 是一种自噬靶向嵌合体 (AUTOTAC),能以不依赖泛素化的方式通过 p62 介导的巨自噬降解 MetAP2,并可抑制肿瘤细胞迁移、诱导程序性细胞死亡,具有抗肿瘤活性 (p62-ZZ ligand (MS-M10044); target-binding ligand (MS-O68938); linker (MS-F04300))。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号